To try and increase cBIN1 levels in cases of heart failure, the scientists turned to a harmless virus commonly used in gene therapy to deliver an extra copy of the cBIN1 gene to heart cells.

The gene therapy focuses on a critical heart protein called cardiac bridging integrator 1 (cBIN1). Reduced levels of cBIN1 impair the heart muscle's ability to contract. Previous studies have ...

TUESDAY, Dec. 10, 2024 (HealthDay News) -- Failing hearts nearly returned to full function in laboratory pigs after they received an experimental gene therapy. New research shows the gene therapy didn ...

For the gene therapy, researchers placed an extra copy of the cBIN1 gene into a hollowed-out virus, then injected the virus into the four pigs. The virus moved through the bloodstream to the heart ...

At the University of Utah, scientists used a new gene therapy that was shown to reverse ... have low levels of cardiac bridging integrator 1 (cBIN1), a critical heart protein.

To try and increase cBIN1 levels in cases of heart failure, the scientists turned to a harmless virus commonly used in gene therapy to deliver an extra copy of the cBIN1 gene to heart cells. They ...

Cell boundaries, labeled in magenta, are more organized after gene therapy, and the level of cBIN1 protein (green) is higher. "Even though the animals are still facing stress on the heart to ...

In an effort to increase protein levels in heart failure, the researchers turned to a harmless virus commonly used in gene therapy to deliver an extra copy of the cBIN1 to heart cells. The virus ...

The therapy involves inserting an extra copy of a gene, which produces a critical heart protein called “cardiac bridging integrator 1”, or cBIN1. The protein forms little baskets – known as ...